 NEW YORK, Dec. 17, 2020 GLOBE NEWSWIRE -- BeyondSpring the Company or BeyondSpring NASDAQ: BYSI, a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia. 